不同剂量阿托伐他汀对冠心病合并微量蛋白尿患者血脂及尿微量白蛋白水平的影响  

Effect of Different Dosages of Atorvastatin on Serum Lipid and Urine Microalbumin in Patients with Coronary Heart Disease Complicated With Microalbuminuria

作　　者：薛娟[1] 刘书培 梁瑾[1] 高磊[2] 

机构地区：[1]河南科技大学第一附属医院检验科,河南洛阳471003 [2]河南科技大学第一附属医院消化内科,河南洛阳471003

出　　处：《中国医院用药评价与分析》2017年第9期1193-1195,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨不同剂量阿托伐他汀对冠心病合并微量蛋白尿患者血脂及尿微量白蛋白水平的影响。方法:选取2015年4月—2016年10月河南科技大学第一附属医院收治的冠心病合并微量蛋白尿患者82例作为研究对象,按照入院顺序分组,单号为观察组,双号为对照组,每组41例。两组患者均给予常规治疗,在此基础上,对照组患者给予阿托伐他汀10 mg/d,观察组患者给予阿托伐他汀20 mg/d。观察两组患者的临床疗效及不良反应发生情况,比较治疗前后血脂及尿微量白蛋白水平。结果:观察组患者的总有效率为95.12%(39/41),明显高于对照组的80.49%(33/41),差异有统计学意义(P<0.05)。治疗后,两组患者总胆固醇、三酰甘油、低密度脂蛋白胆固醇、尿微量白蛋白水平均明显低于治疗前,且观察组患者明显低于对照组;两组患者高密度脂蛋白胆固醇水平明显高于治疗前,且观察组患者明显高于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:阿托伐他汀能改善冠心病合并微量蛋白尿患者的血脂水平,降低尿微量白蛋白水平,且20 mg/d的疗效优于10 mg/d。OBJECTIVE： To probe into the effect of different dosages of atorvastatin on serum lipid and urine microalbumin in patients with coronary heart disease（ CHD） complicated with microalbuminuria. METHODS： 82 patients with CHD complicated with microalbuminuria admitted into the First Affiliated Hospital of Henan University of Science and Technology from Apr. 2015 to Oct. 2016 were selected and divided into observation group and control group according to the admission sequences（ odd numbers were set as observation group,even numbers were set as control group）,with 41 cases in each group. Both groups were given conventional therapy,in addition,the control group was treated with atorvastatin for 10 mg/d,while the observation group was given atorvastatin for 20 mg/d. The clinical efficacy and incidence of adverse drug reactions of both groups were observed,levels of serum lipid and m ALB of two groups before and after treatment were compared. RESULTS： The total effective rate of observation group was95. 12%（ 39/41）,which was significantly higher than that of the control group [80. 49%（ 33/41） ],with statistically significant difference（ P〈0. 05）. After treatment,levels of TC,TG,LDL-C and m ALB of both groups were significantly lower than those of before treatment,and those of observation group were significantly lower than the control group; level of HLD-C of both groups were significantly higher than that of before treatment,and that of observation group was significantly higher than the control group,with statistically significant differences（ P〈0. 05）.There was no significant difference in the incidence of adverse reactions between two groups（ P〉0. 05）.CONCLUSIONS： Atrovastatin can effectively improve the levels of serum lipid of patients with CHD complicated withmicroalbuminuria,and reduce the urine microalbumin. Besides,the efficacy of dosage of 20 mg/d is better than that of 10 mg/d.

关 键 词：冠心病 微量蛋白尿 血脂 阿托伐他汀 

分 类 号：R972.6[医药卫生—药品]